Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Fiche publication
Date publication
janvier 2023
Journal
Gynecologic oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr FAVIER Laure, Dr KAMINSKY Marie-Christine, Dr GANTZER Justine
Tous les auteurs :
Ferron G, De Rauglaudre G, Becourt S, Delanoy N, Joly F, Lortholary A, You B, Bouchaert P, Malaurie E, Gouy S, Kaminsky MC, Meunier J, Alexandre J, Berton D, Dohollou N, Dubot C, Floquet A, Favier L, Venat-Bouvet L, Fabbro M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Desauw C, Del Piano F, Leheurteur M, Bonichon-Lamichhane N, Rastkhah M, Follana P, Gantzer J, Ray-Coquard I, Pujade-Lauraine E
Lien Pubmed
Résumé
The oral anti-angiogenic therapy nintedanib prolongs progression-free survival (PFS) when combined with chemotherapy after primary surgery for advanced epithelial ovarian cancer. The randomized phase II CHIVA trial evaluated the impact of combining nintedanib with neoadjuvant chemotherapy (NACT) for epithelial ovarian cancer.
Mots clés
Anti-angiogenic, Interval debulking surgery, Neoadjuvant, Nintedanib, Ovarian cancer
Référence
Gynecol Oncol. 2023 01 25;170:186-194